96 reports of this reaction
1.5% of all COLESTIPOL HYDROCHLORIDE reports
#14 most reported adverse reaction
CROHN^S DISEASE is the #14 most commonly reported adverse reaction for COLESTIPOL HYDROCHLORIDE, manufactured by Pharmacia & Upjohn Company LLC. There are 96 FDA adverse event reports linking COLESTIPOL HYDROCHLORIDE to CROHN^S DISEASE. This represents approximately 1.5% of all 6,329 adverse event reports for this drug.
Patients taking COLESTIPOL HYDROCHLORIDE who experience crohn^s disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CROHN^S DISEASE is a less commonly reported adverse event for COLESTIPOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to crohn^s disease, the following adverse reactions have been reported for COLESTIPOL HYDROCHLORIDE:
The following drugs have also been linked to crohn^s disease in FDA adverse event reports:
CROHN^S DISEASE has been reported as an adverse event in 96 FDA reports for COLESTIPOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CROHN^S DISEASE accounts for approximately 1.5% of all adverse event reports for COLESTIPOL HYDROCHLORIDE, making it a notable side effect.
If you experience crohn^s disease while taking COLESTIPOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.